A Randomized Clinical Trial of Selective Laser Trabeculoplasty Versus Argon Laser Trabeculoplasty in Patients With Pseudoexfoliation : Journal of Glaucoma

Secondary Logo

Journal Logo

Original Studies

A Randomized Clinical Trial of Selective Laser Trabeculoplasty Versus Argon Laser Trabeculoplasty in Patients With Pseudoexfoliation

Kent, Shefalee S. MD, FRCSC*; Hutnik, Cindy M. L. MD, PhD, FRCSC*; Birt, Catherine M. MD, FRCSC; Damji, Karim F. MD, FRCSC; Harasymowycz, Paul MD, FRCSC§; Si, Francie MD, MSc*; Hodge, William MD, PhD, FRCSC*; Pan, Irene MSc*; Crichton, Andrew MD, FRCSC

Author Information
Journal of Glaucoma 24(5):p 344-347, June/July 2015. | DOI: 10.1097/IJG.0b013e31829e55e4

Abstract

Purpose: 

To evaluate the efficacy of selective laser trabeculoplasty (SLT) versus argon laser trabeculoplasty (ALT) in lowering the intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension secondary to pseudoexfoliation.

Design: 

Multicentered randomized clinical trial.

Participants 

A total of 76 eyes from 60 patients with pseudoexfoliation and uncontrolled IOP were recruited from 5 Canadian academic institutions. Patients with prior laser trabeculoplasty, ocular surgery within 6 months, previous glaucoma surgery, an advanced visual field defect, current steroid use, and monocular patients were excluded.

Methods: 

Eyes were randomized to receive either 180-degree SLT or 180-degree ALT by a nonblocked randomization schedule stratified by center.

Main Outcome Measurement: 

The primary outcome was the change in IOP at 6 months versus baseline and secondary outcomes included change in number of glaucoma medications after laser. Baseline variables included age, sex, angle grade, angle pigmentation, and number of glaucoma medications.

Results: 

Of the 76 eyes, 45 eyes received SLT and 31 eyes received ALT. The overall age was 72.9 years (65% females). The baseline IOPs in the SLT and ALT groups were 23.1 and 25.2 mm Hg, respectively (P=0.03). The IOP reduction 6 months after SLT was −6.8 mm Hg and post-ALT was −7.7 mm Hg (P>0.05). The SLT group had reduced glaucoma medications by 0.16 medications at 6 months and the ALT group had no decrease in medications over the same time period (P=0.59). There were no postlaser IOP spikes in either group.

Discussion: 

ALT and SLT are equivalent in lowering IOP at 6 months posttreatment in patients with PXF.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid